- Home >
- Clinicals Trials >
- MYTX-011-01
Retour à la liste des essais cliniquesLung cancer
MYTX-011-01
MYTX-011-01 : A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer · KisMET-01
- Ouvert à Paris depuis le : 18/07/2024
- Public cible : Adult
- Phase : Phase I
Description de l'essai
To evaluate the safety and tolerability of;MYTX-011;À To determine the RP2D and/or MTD of MYTX-011;Incidence and severity of TEAEs, AEs, and;clinically significant changes from baseline in vital;signs, ECGs, and laboratory parameters;À The RP2D will be selected as a biologically active;dose at or below the MTD (or the highest dose;tested if the MTD is not identified during the;study);À MTD will be determined by DLTs during Cycle 1.;The observation period for DLTs is Cycle 1.
Url of the trialInvestigateur principal
